Instruction for use: Rutacid

Active substance Hydrotalcite

ATX Code A02AD04 Hydrotalcite

Pharmacological group

Antacids

Nosological classification (ICD-10)

K21.0 Gastro-oesophageal reflux with oesophagitis

Reflux gastritis, Reflux esophagitis, Erosive and ulcerative esophagitis

K25 Gastric ulcer

Helicobacter pylori, Pain syndrome in gastric ulcer, Pain syndrome in gastric ulcer and duodenal ulcer, Inflammation of the gastric mucosa, Inflammation of the gastrointestinal mucosa, Benign gastric ulcer, The disease of the stomach and duodenum, asotsiirovannoe with Helicobacter pylori, Aggravation gastroduodenita on the background of peptic ulcer, Exacerbation of peptic ulcer, The aggravation of gastric ulcer, The organic gastrointestinal disease, Peptic ulcer of the stomach and duodenum, Postoperative gastric ulcer, Recurrent ulcers, Symptomatic gastric ulcers, Chronic inflammatory disease of the upper gastrointestinal tract, associated with Helicobacter pylori, Helicobacter pylori eradication, Erosive and ulcerative lesions of the stomach, Erosive lesions of the stomach, The erosion of the gastric mucosa, Peptic ulcer disease, Stomach ulcer, Gastric lesion, Ulcerative lesions of the stomach, Symptomatic ulcers of the stomach and duodenum

K26 Duodenal Ulcer

Pain with duodenal ulcer, Pain syndrome in gastric ulcer and duodenal ulcer, The disease of the stomach and duodenum, asotsiirovannoe with Helicobacter pylori, Exacerbation of peptic ulcer, The worsening of duodenal ulcer, Peptic ulcer of the stomach and duodenum, Relapse of duodenal ulcers, Symptomatic ulcers of the stomach and duodenum, Helicobacter pylori eradication, Erosive and ulcerative lesions of the duodenum, Erosive-ulcerative lesions of duodenal ulcers associated with Helicobacter pylori, Erosive lesions of the duodenum, Duodenal ulcer, Ulcerative lesions of the duodenum]

K29.7 Unspecified gastritis

Gastritis with low acidityá Gastritisá Gastritis with a normal secretory functionáGastritisá Erosive gastritis

K31.8.2 * Hyperacidity of gastric juice

Pathological hypersecretion, Hyperacid indigestion, Hyperadic states, Increased secretion of gastric juice, Increased acid formation, Hyperacidosis,Hyper secretion of gastric juice, Increased acidity of gastric juice, High acidity

R12 Heartburn

Composition

Tablets chewing 1 tab.

active substance:

hydrotalcite 500 mg

auxiliary substances: mannitol - 836 mg; sodium saccharinate - 0.6 mg; sodium carboxymethyl starch - 12 mg; talc - 35 mg; magnesium stearate - 14 mg; peppermint flavor - 2.4 mg

Description of dosage form

Round tablets white or almost white with a bevelled edge and a slight minty odor.

pharmachologic effect

Pharmacological action - antacid.

Pharmacodynamics

The hydrotalcite has a stratified-mesh structure with a low content of aluminum and magnesium. The release of aluminum and magnesium ions occurs gradually depending on the pH of the gastric juice. The drug provides a fast and long-lasting neutralization of hydrochloric acid with maintaining the pH close to normal. Has a protective effect on the mucous membrane of the stomach. Reduces the proteolytic activity of pepsin, binds bile acids.

Pharmacokinetics

The release of magnesium and aluminum ions occurs in the stomach gradually, depending on the pH value. Absorption of the drug occurs in the small intestine. After ingestion, the content of magnesium and aluminum ions in the blood plasma temporarily increases, but no penetration into the nerve and bone tissue occurs (with normal kidney function). The absorbed part is excreted by the kidneys.

Indications

acute gastritis, chronic gastritis with increased secretory function in the exacerbation phase;

acute and chronic duodenitis;

peptic ulcer of the stomach and duodenum;

reflux esophagitis;

discomfort and epigastric pain, heartburn, acidic eructations after dietary errors, excessive alcohol consumption, and medication.

Contraindications

increased sensitivity to hydrotalcite;

children's age (up to 6 years).

With caution: chronic renal failure, hypophosphatemia.

pregnancy and lactation

Confirmed data on the undesirable effects of hydrotalcite during pregnancy and breastfeeding there. The use of the drug during pregnancy is possible if the potential benefit to the mother exceeds the possible risk to the fetus. The drug does not penetrate into breast milk, so breast-feeding women can take the drug.

Side effects

When taking the drug, side effects occur rarely. Allergic reactions, diarrhea, eructation are possible.

Interaction

Rutacid® reduces the absorption of tetracycline antibiotics, fluoroquinolones (ciprofloxacin, ofloxacin), coumarins, iron preparations.

Dosing and Administration

Inside, thoroughly chewing.

Adults and children over 12 years of age: 1-2 tablets. 1 hour after meals 3-4 times a day and at bedtime.

Children from 6 to 12 years: 1 table. 2 times a day.

Treatment should be continued for 4 weeks.

Overdose

There were no cases of overdose with Rutacid®.

special instructions

The interval between the use of the drug and other drugs should be at least 1-2 hours.

It is not recommended to use the drug Rutacid® simultaneously with acid-containing beverages (juices, wine).

The drug Rutacid® does not contain sucrose, therefore it can be used by patients with diabetes mellitus.

Polyols (mannitol) can cause diarrhea.

Influence on the ability to drive and other mechanisms. Does not affect.

Form of issue

Tablets are chewable, 500 mg. For 10 tab. in the blister pack. For 2 or 6 blisters packaged in a cardboard box.

Conditions of leave from pharmacies

Without recipe.

storage conditions

At a temperature not exceeding 30 ° C.

Keep out of the reach of children.

Shelf Life

5 years.

Do not use after the expiry date printed on the package.